In type 2 diabetics with microalbuminuria, irbesartan reduces albumin excretion independent of its antihypertensive effect, according to the results of a randomized controlled trial reported in the November issue of Diabetes Care.
“Angiotensin-converting enzyme (ACE) inhibitors delay the progression from incipient to overt diabetic nephropathy and reduce albumin excretion rate (AER), independently of blood pressure,” write Ferdinando C. Sasso, MD, PhD, and colleagues from the Second University of Naples in Italy.
“Irbesartan is a long-acting angiotensin-type 1 receptor antagonist (AT1-RA) with a dose-related action and a good tolerability profile.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!